Recurrent mutations in IDH1/IDH2—prevalent in gliomas (accounting for 80%) (59), acute myeloid leukemia (AML, accounting for 20%) (62, 63), and chondrosarcomas (accounting for 80%) (64, 65) but occurring in <1% of CRC cases (66)—drive neomorphic production of the oncometabolite 2-hydroxyglutarate (2-HG). Here, IDH2 is linked to acute myeloid leukemia.